Featured Jobs
|
Defined Benefit Plan Consultant/Actuarial Analyst Sentinel Group
|
|
Strategic Retirement Plan Consultant Retirement Plan Consultants
|
|
MAP Retirement
|
|
Pattison Pension
|
|
Sentinel Group
|
|
DWC - The 401(k) Experts
|
|
BPAS
|
|
Regional Vice President, Sales MAP Retirement
|
|
Retirement Relationship Manager MAP Retirement
|
|
MAP Retirement
|
|
Pension Investors Corporation
|
|
Plan Administrator, Defined Benefit & Cash Balance The Pension Source
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
How an $84,000 Drug Got Its Price: 'Let's Hold Our Position ... Whatever the Headlines'
The Washington Post; subscription may be required 
Dec. 2, 2015
"Gilead gained federal approval for its drug Sovaldi in late 2013 and ultimately settled on the price of $84,000 for a 12-week course of treatment. To the company, that price seemed to deliver the right balance: value to shareholders while also not so high that insurers would 'hinder patient access to uncomfortable levels' ... But they also got more than they bargained for: an outpouring of outrage from the public, a backlash from government and private payers, and political scrutiny."
|
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |